Browsing Tag
BIMZELX
2 posts
UCB’s BIMZELX shows sustained inflammation control at three years in psoriatic arthritis and axial spondyloarthritis
Discover how UCB’s BIMZELX three-year data show lasting inflammation control in PsA and axSpA—find out what’s next for the treatment landscape.
UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global…